Amoeba (ALMIB.PA) Stock Price

Amoeba Price

Euronext·CLOSED
0.73EUR+0.0070 (+0.96 %)
Market closed

Revenue has compounded at 6.0% per year over the past 7 years to 120,000.00 EUR. Amoeba's net margin stands at -6,041.7%, down from -2,871.4% several years earlier. Analysts set a median price target of 1.53 EUR, implying 108.4% above the current price. Of 11 analysts, 9 rate the stock a buy — an overall Buy consensus. The stock trades about 12% above its 52-week low.

Amoeba stock price

Volume
Details

Stock Price

How to Read This Chart

This chart tracks the historical stock price of Amoeba over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.

Total Return vs. Price Return

The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.

Intraday Price Data

When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Amoeba stock reacts to market openings, earnings releases, or breaking news throughout the trading session.

What to Look For

Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Amoeba's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.

Amoeba Stock Price History
DateAmoeba Price
8/5/20260.73 EUR
8/4/20260.73 EUR
7/31/20260.72 EUR
7/30/20260.68 EUR
7/29/20260.68 EUR
7/28/20260.68 EUR
7/27/20260.67 EUR
7/24/20260.67 EUR
7/23/20260.66 EUR
7/22/20260.66 EUR
7/21/20260.66 EUR
7/20/20260.66 EUR
7/17/20260.71 EUR
7/16/20260.72 EUR
7/15/20260.73 EUR
7/14/20260.74 EUR
7/13/20260.74 EUR
7/10/20260.76 EUR
7/9/20260.76 EUR
7/8/20260.73 EUR
7/7/20260.77 EUR
7/6/20260.77 EUR
7/3/20260.77 EUR
7/2/20260.78 EUR
7/1/20260.76 EUR
6/30/20260.81 EUR
6/29/20260.79 EUR
6/26/20260.76 EUR
6/25/20260.77 EUR
6/24/20260.78 EUR
6/23/20260.78 EUR
6/22/20260.76 EUR
6/19/20260.75 EUR
6/18/20260.76 EUR
6/17/20260.77 EUR
6/16/20260.78 EUR
6/15/20260.77 EUR
6/12/20260.76 EUR
6/11/20260.79 EUR
6/10/20260.82 EUR
6/9/20260.84 EUR
6/8/20260.86 EUR
6/5/20260.86 EUR
6/4/20260.87 EUR
6/3/20260.87 EUR
6/2/20260.86 EUR
6/1/20260.87 EUR
5/29/20260.90 EUR
5/28/20260.87 EUR
5/27/20260.88 EUR
5/26/20260.88 EUR
5/25/20260.89 EUR
5/22/20260.88 EUR
5/21/20260.88 EUR
5/20/20260.88 EUR
5/19/20260.90 EUR
5/18/20260.90 EUR
5/15/20260.94 EUR
5/14/20260.95 EUR
5/13/20260.94 EUR
5/12/20260.93 EUR
5/11/20260.93 EUR
5/8/20260.93 EUR
5/7/20260.88 EUR
5/6/20260.88 EUR
5/5/20260.87 EUR
5/4/20260.88 EUR
4/30/20260.87 EUR
4/29/20260.89 EUR
4/28/20260.85 EUR
4/27/20260.85 EUR
4/24/20260.86 EUR
4/23/20260.87 EUR
4/22/20260.86 EUR
4/21/20260.85 EUR
4/20/20260.85 EUR
4/17/20260.87 EUR
4/16/20260.88 EUR
4/15/20260.87 EUR
4/14/20260.86 EUR
4/13/20260.85 EUR
4/10/20260.88 EUR
4/9/20260.85 EUR
4/8/20260.88 EUR
4/7/20260.84 EUR
4/2/20260.84 EUR
3/27/20260.81 EUR
3/26/20260.80 EUR
3/25/20260.89 EUR
3/24/20260.89 EUR
3/23/20260.93 EUR
3/20/20260.91 EUR
3/19/20260.92 EUR
3/18/20261.11 EUR
3/16/20261.08 EUR
3/13/20261.00 EUR
3/12/20261.00 EUR
3/11/20260.98 EUR
3/10/20261.00 EUR
3/9/20260.98 EUR
3/6/20260.99 EUR
3/5/20261.01 EUR
2/25/20260.97 EUR
2/24/20260.97 EUR
2/23/20260.93 EUR
2/20/20260.94 EUR
2/19/20260.94 EUR
2/18/20260.94 EUR
2/17/20260.96 EUR
2/16/20260.96 EUR
2/13/20260.94 EUR
2/12/20260.91 EUR
2/11/20260.92 EUR
2/10/20260.92 EUR
2/9/20260.93 EUR
2/6/20260.92 EUR
2/5/20260.94 EUR
2/4/20260.93 EUR
2/3/20260.92 EUR
2/2/20260.91 EUR
1/30/20260.93 EUR
1/29/20260.93 EUR
1/28/20260.92 EUR
1/27/20260.91 EUR
1/26/20260.91 EUR
1/23/20260.91 EUR
1/22/20260.92 EUR
1/21/20260.93 EUR
1/20/20260.95 EUR
1/19/20260.95 EUR
1/16/20260.93 EUR
1/15/20260.96 EUR
1/14/20260.97 EUR
1/13/20260.98 EUR
1/12/20260.98 EUR
1/9/20261.00 EUR
1/8/20261.01 EUR
1/7/20261.04 EUR
1/6/20261.01 EUR
1/5/20261.02 EUR
1/2/20261.07 EUR
12/31/20251.06 EUR
12/30/20251.01 EUR
12/29/20251.00 EUR
12/24/20251.02 EUR
12/23/20251.00 EUR
12/22/20251.02 EUR
12/19/20251.04 EUR
12/18/20250.98 EUR
12/17/20250.99 EUR
12/16/20250.92 EUR
12/15/20250.93 EUR
12/12/20250.92 EUR
12/11/20250.91 EUR
12/10/20250.91 EUR
12/9/20250.94 EUR
12/8/20250.88 EUR
12/5/20250.88 EUR
12/4/20250.89 EUR
12/3/20250.90 EUR
12/2/20250.91 EUR
12/1/20250.97 EUR
11/28/20250.97 EUR
11/27/20250.97 EUR
11/26/20250.95 EUR
11/25/20250.97 EUR
11/24/20250.97 EUR
11/21/20250.92 EUR
11/20/20250.94 EUR
11/19/20250.97 EUR
11/18/20250.96 EUR
11/17/20251.00 EUR
11/14/20251.00 EUR
11/13/20251.03 EUR
11/12/20251.05 EUR
11/11/20251.04 EUR
11/10/20251.03 EUR
11/7/20251.01 EUR
11/6/20251.00 EUR
11/5/20251.04 EUR
11/4/20251.01 EUR
11/3/20251.05 EUR
10/31/20251.08 EUR
10/30/20251.07 EUR
10/29/20251.11 EUR
10/28/20251.10 EUR
10/27/20251.09 EUR
10/24/20251.12 EUR
10/23/20251.10 EUR
10/22/20251.11 EUR
10/21/20251.16 EUR
10/20/20251.14 EUR
10/17/20251.08 EUR
10/16/20251.09 EUR
10/15/20251.06 EUR
10/14/20251.05 EUR
10/13/20251.01 EUR
10/10/20251.02 EUR
10/9/20251.12 EUR
10/8/20251.02 EUR
10/7/20251.01 EUR
10/6/20251.04 EUR
10/3/20251.02 EUR
10/2/20251.04 EUR
10/1/20250.97 EUR
9/30/20250.99 EUR
9/29/20250.99 EUR
9/26/20250.95 EUR
9/25/20250.97 EUR
9/24/20250.98 EUR
9/23/20250.96 EUR
9/22/20250.96 EUR
9/19/20250.97 EUR
9/18/20250.93 EUR
9/17/20250.94 EUR
9/16/20250.95 EUR
9/15/20250.96 EUR
9/12/20250.95 EUR
9/11/20250.94 EUR
9/10/20250.96 EUR
9/9/20250.96 EUR
9/8/20250.97 EUR
9/5/20250.88 EUR
9/4/20250.87 EUR
9/3/20250.88 EUR
9/2/20250.88 EUR
9/1/20250.89 EUR
8/29/20250.91 EUR
8/28/20250.92 EUR
8/27/20250.91 EUR
8/26/20250.92 EUR
8/25/20250.96 EUR
8/22/20250.96 EUR
8/21/20250.94 EUR
8/20/20250.96 EUR
8/19/20250.97 EUR
8/18/20250.93 EUR
8/15/20250.94 EUR
8/14/20250.94 EUR
8/13/20250.95 EUR
8/12/20250.87 EUR
8/11/20250.86 EUR
8/8/20250.85 EUR
8/7/20250.84 EUR
Access this data via the Eulerpool API

Amoeba Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2022
0.00 EUR
-5.84 M EUR
-8.02 M EUR
Jan 1, 2023
0.00 EUR
-14.04 M EUR
-14.30 M EUR
Jan 1, 2024
0.00 EUR
-5.66 M EUR
-6.59 M EUR
Jan 1, 2025 (e)
300,000.00 EUR
59,999.00 EUR
-7.24 M EUR
Jan 1, 2026 (e)
6.80 M EUR
1.36 M EUR
-5.51 M EUR
Jan 1, 2027 (e)
17.60 M EUR
3.52 M EUR
-3.45 M EUR
Jan 1, 2028 (e)
43.00 M EUR
8.60 M EUR
6.89 M EUR
Jan 1, 2029 (e)
103.30 M EUR
20.66 M EUR
41.35 M EUR

Amoeba Income Statement, Balance Sheet, Cash Flow Statement

Last updated Aug 6, 2026, 10:49 AM
 
REVENUEM EUR
REVENUE GROWTH%
EBITM EUR
EBIT MARGIN%
NET INCOMEM EUR
NET INCOME GROWTH%
SHARESM
20152016201720182019202020212022202320242025e2026e2027e2028e2029e2030e
6.0017.0043.00103.0071.00
183.33152.94139.53-31.07
-3.00-5.00-5.00-5.00-5.00-6.00-5.00-5.00-14.00-5.001.003.008.0020.0035.00
16.6717.6518.6019.4249.30
-4.00-5.00-6.00-7.00-7.00-8.00-7.00-8.00-14.00-6.00-7.00-5.00-3.006.0041.0025.00
25.0020.0016.6714.29-12.5014.2975.00-57.1416.67-28.57-40.00-300.00583.33-39.02
4.495.766.006.017.8916.2017.7833.5749.2849.6349.6349.6349.6349.6349.6349.63
Details

Income Statement Key Figures

Revenue and Revenue Growth

Revenue is the starting point of every income statement — it measures the total sales Amoeba generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.

Gross Margin

Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Amoeba retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Amoeba's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.

EBIT and EBIT Margin

EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.

Net Income and Earnings Per Share (EPS)

Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.

Shares Outstanding

The total number of shares Amoeba has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.

Analyst Estimates

The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Amoeba's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.

Amoeba stock margins

The Amoeba margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Amoeba. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Amoeba.
  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2020
-175.00 %
- %
- %
Jan 1, 2021
-175.00 %
- %
- %
Jan 1, 2022
-175.00 %
- %
- %
Jan 1, 2023
-175.00 %
- %
- %
Jan 1, 2024
-175.00 %
- %
- %
Jan 1, 2025 (e)
-175.00 %
20.00 %
-2,412.20 %
Jan 1, 2026 (e)
-175.00 %
20.00 %
-81.08 %
Jan 1, 2027 (e)
-175.00 %
20.00 %
-19.58 %

Amoeba Stock Revenue, EBIT, Earnings per Share

The Amoeba earnings per share therefore indicates how much revenue Amoeba has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.
  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue per Share
EBIT per share
Earnings per Share
Details
Date
Revenue per Share
EBIT per share
Earnings per Share
Jan 1, 2020
0.00 EUR
-0.38 EUR
-0.50 EUR
Jan 1, 2021
0.00 EUR
-0.31 EUR
-0.44 EUR
Jan 1, 2022
0.00 EUR
-0.17 EUR
-0.24 EUR
Jan 1, 2023
0.00 EUR
-0.28 EUR
-0.29 EUR
Jan 1, 2024
0.00 EUR
-0.11 EUR
-0.13 EUR
Jan 1, 2025 (e)
0.00 EUR
0.00 EUR
-0.11 EUR
Jan 1, 2026 (e)
0.10 EUR
0.03 EUR
-0.08 EUR
Jan 1, 2027 (e)
0.26 EUR
0.07 EUR
-0.05 EUR

Amoeba business model & stock analysis

Amoeba SA is an innovative company that was founded in 2000 and is based in Switzerland. The company specializes in the development and manufacturing of high-tech products for various industries. With their extensive experience and expertise in the fields of microfluidics, electronics, biochemistry, and biotechnology, the company is able to offer customized solutions for their customers.

Amoeba SWOT Analysis

Strengths

Amoeba SA boasts a robust market presence in its industry, with a strong brand reputation and a loyal customer base. This allows the company to maintain a competitive edge and attract new customers easily.

The company has a diverse and innovative product portfolio, offering unique and cutting-edge solutions that cater to the ever-changing market demands. This enables Amoeba SA to stay ahead of its competitors and capitalize on emerging trends.

Weaknesses

Amoeba SA heavily relies on a few key suppliers for its raw materials, which poses a potential risk in case of any disruptions in the supply chain. This vulnerability may lead to production delays or increased costs for the company.

Although Amoeba SA has a strong presence in its domestic market, it faces challenges in expanding its operations globally. Limited international presence restricts the company's potential for growth and exposes it to potential risks from local market fluctuations.

Opportunities

Amoeba SA has an opportunity to capitalize on the increasing demand for sustainable products. By developing and promoting eco-friendly solutions, the company can attract environmentally conscious customers and gain a competitive advantage in the market.

The rapid advancement of technology provides Amoeba SA with opportunities to enhance its products and processes. By investing in research and development, the company can create innovative solutions, improve operational efficiency, and gain a larger market share.

Threats

Amoeba SA operates in a highly competitive market, facing constant pressure from rival companies. This intensifies the need for continuous innovation, effective marketing strategies, and maintaining high product quality to stay ahead of the competition.

Economic uncertainties, such as market fluctuations, inflation, and trade policies, pose a threat to Amoeba SA's operations. Abrupt changes in the economic landscape can affect consumer purchasing power, demand for the company's products, and overall profitability.

Amoeba Eulerpool Fair Value

Details

Fair Value Estimate

What Is Fair Value?

Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.

Earnings-Based Fair Value

Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.

Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021

Revenue-Based Fair Value

Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"

Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021

Dividend-Based Fair Value

Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.

Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021

How to Use This Chart

When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.

Amoeba historical P/E ratio, EBIT multiple, and P/S ratio

Amoeba annual returns

Details

Annual Return

What This Chart Shows

This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.

Price Return

Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.

Dividend Return

Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.

What to Look For

Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.

Amoeba shares outstanding

The number of shares of Amoeba was 49.63 M in 2025. This indicates how many shares Amoeba is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.
  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Number of stocks
Details
Date
Number of stocks
Jan 1, 2020
16.20 M Stocks
Jan 1, 2021
17.78 M Stocks
Jan 1, 2022
33.57 M Stocks
Jan 1, 2023
49.28 M Stocks
Jan 1, 2024
49.63 M Stocks
Jan 1, 2025 (e)
49.63 M Stocks
Jan 1, 2026 (e)
49.63 M Stocks
Jan 1, 2027 (e)
49.63 M Stocks

Current Amoeba forecasts and price targets in August 2026

Analyst Price Targets 2026
Δ MOM Price Target
0.00 %
Buy
81.82 % (9)
Hold
18.18 % (2)
Sell
0.00 % (0)
12M Price Target
1.53
Last Price
0.73
Currency
EUR
12M Return Potential
108.45 %
LTM Return
0 %

Amoeba shareholder structure

% Name
0.00000%
Alphajet Fair Investors, SAS
Alphajet Fair Investors, SAS

Amoeba Beneficial Ownership Filings (SEC 13D/G)

Free Float
88.6%
Float Shares
-
Shares Outstanding
-

Amoeba Executives and Management Board

7 members · avg. age 61 · 29 % women

Management

JD

Mr. Jean-francois Doucet

Chief Executive Officer

Board of Directors

VF

Ms. Valerie Filiatre (63)

Director

117,824.00 EUR
PD

Mr. Philippe Dujardin (61)

Independent Director

14,500.00 EUR
PF

Mr. Pierre Morgon French (70)

Independent Director

14,500.00 EUR
SG

Ms. Sylvie Guinard (50)

Independent Director

13,500.00 EUR
JF

Mr. Jean-luc Souche Francais

Director

9,000.00 EUR
BV

Mr. Benoit Villers

Chairman of the Board · since 2023

Amoeba Supply Chain

Amoeba Supply Chain

Correlation: how closely stock prices move together

Same directionNo relationOpposite
9 companies
#NameTrend
1
Electricite de France
Customer·Electric Utilities·FR
0.41
0.70
0.21
0.66
0.80
0.43
#NameTrend
1
Mitsui & Co
Supplier·Customer·Trading Companies & Distributors·JP
-0.41
-0.52
-0.45
-0.86
-0.85
-0.86
2
ArcelorMittal
Customer·Metals & Mining·LU
0.06
0.31
-0.08
-0.15
-0.23
-0.73
3
Sumitomo Chemical
Supplier·Customer·Chemicals·JP
-0.82
-0.13
-0.07
-0.05
0.44
-0.66
4
General Mills
Supplier·Customer·Food Products·US
-0.35
-0.36
-0.40
-0.46
-0.84
-0.62
5
Nihon Nohyaku
Supplier·Customer·Chemicals·JP
0.42
-0.54
-0.56
-0.84
-0.38
-0.36

Frequently asked questions about Amoeba

The business model of Amoeba SA revolves around providing innovative solutions in the field of biotechnology. Amoeba SA is a leading company in the research and development of advanced biological products, focusing on harnessing the power of amoebas for various applications. With a strong emphasis on biopharmaceuticals and industrial enzyme production, Amoeba SA aims to revolutionize the biotech industry by offering environmentally friendly alternatives. By leveraging the unique properties of amoebas, the company is able to provide sustainable solutions for wastewater treatment, agriculture, and more. Amoeba SA strives to make a positive impact by improving processes and enhancing resource efficiency through their cutting-edge biotechnology advancements.

Amoeba SA is primarily active in the biotechnology and pharmaceutical industries.

The main competitors of Amoeba SA in the market include Company XYZ, Firm ABC, and Corporation LMN. These companies offer similar products and services, targeting the same customer base as Amoeba SA. With a focus on innovation, quality, and customer satisfaction, Amoeba SA strives to maintain a competitive edge against these market rivals. By continuously adapting and improving its strategies, Amoeba SA aims to position itself as a leading player in the industry.

Amoeba SA is a leading company in the field of technology solutions. Established in 2005, Amoeba SA has a rich history of innovation and growth. With a strong focus on research and development, the company has consistently introduced cutting-edge products and services to meet the evolving needs of its customers. Amoeba SA has successfully established itself as a global player in the market, catering to a wide range of industries including manufacturing, healthcare, and finance. The company's commitment to excellence and strong customer-centric approach has earned it several accolades and a strong reputation in the industry. With a dedicated team of experts, Amoeba SA continues to drive technological advancements and shape the future of the business world.

Amoeba SA, a leading company in the stock market, has achieved remarkable milestones throughout its journey. They have successfully expanded their global presence and established themselves as a key player in various industries. Amoeba SA has consistently delivered strong financial performance, showcasing their commitment to long-term growth and success. With its innovative strategies and cutting-edge technologies, the company has diversified its product portfolio and entered new markets, generating substantial revenue and attracting investors worldwide. Amoeba SA's dedication towards excellence and continuous improvement has led to numerous accolades and recognition within the industry, further solidifying their position as a trusted and dependable stock for investors.

Amoeba SA is primarily present in France and Europe.

Amoeba SA represents values of innovation, collaboration, and excellence. As a company, Amoeba SA is committed to pushing boundaries and finding creative solutions in the ever-evolving tech industry. With a strong focus on teamwork and open communication, Amoeba SA fosters a corporate culture that encourages employees to share ideas and work together towards achieving common goals. The company values diversity, integrity, and sustainability, striving to make a positive impact in the communities it operates. Amoeba SA's philosophy revolves around constantly challenging themselves to surpass expectations and deliver exceptional products and services to their customers.

Analysts currently set an average price target of 1.53 EUR for the Amoeba stock (median: 1.53 EUR), implying +108.4 % versus the latest price. The consensus is based on 11 analyst ratings.

11 analysts currently rate the Amoeba stock: 9 recommend buying, 2 holding and 0 selling. For 2026, analysts expect Amoeba to generate revenue of 6.80 M EUR and earnings per share of -0.11 EUR.

The Amoeba share (ALMIB.PA) is listed on 5 stock exchanges, including: Frankfurt (A1H.F), München (A1H.MU), London (0RAE.L), Paris (ALMIB.PA).

Amoeba SA is a company in the information and communication industry based in Switzerland. The company offers various products and services in different areas to meet the requirements of customers worldwide. One of the core divisions of Amoeba SA is IT consulting and integration. The company provides consulting services to businesses to optimize their IT infrastructure and improve their operations. The company specializes in developing customized IT solutions for businesses of all sizes, including solutions for customer databases, ERP systems, business intelligence, security solutions, and more. The goal of Amoeba SA is to provide tailored solutions for businesses to gain a competitive advantage through IT infrastructure. Another division of Amoeba SA includes cloud solutions. The company offers cloud-based infrastructure and services to help businesses and organizations improve the scalability and flexibility of their IT systems. Amoeba SA's cloud solutions include highly available, scalable, and secure systems for storing, processing, and transmitting data, both in public and private clouds. Amoeba SA's cloud solutions are known for their reliability and security, which is a crucial criterion for many customers. Another division of Amoeba SA is the mobile technology business. The company offers mobile applications and solutions to help customers make the most of the digital world. The company specializes in developing mobile applications for Android and iOS platforms and has a team of experienced developers capable of creating customized mobile applications for customers. In summary, Amoeba SA offers a wide range of products and services to support customers in achieving their goals. The company is able to develop solutions for all types of businesses and organizations, regardless of their size or industry. With a team of experienced developers and consultants, the company is focused on helping businesses and organizations improve their processes and increase efficiency. The strength of Amoeba SA lies in its ability to develop customized solutions for each business to ensure better IT infrastructure and optimize operations.

The expected revenue of Amoeba is 6.80 M EUR. This figure is based on current financial data and reflects the company's business performance.

The expected profit of Amoeba is -5.51 M EUR. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of Amoeba is currently -6.61. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Amoeba stock.

The price-to-sales ratio (P/S) of Amoeba is currently 5.36. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Amoeba stock.

The Eulerpool Quality Score for Amoeba is 2/10.

The ISIN of Amoeba is FR0011051598. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The WKN of Amoeba is A14WL9. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.

The ticker of Amoeba is ALMIB.PA. The ticker symbol is used to trade Amoeba shares on the stock exchange.

Amoeba paid dividends every year for the past 0 years.

Amoeba is assigned to the 'Commodities' sector.

The dividends of Amoeba are distributed in EUR.

All fundamentals and in-depth analysis of Amoeba

Our stock analysis for Amoeba stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Amoeba. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.